Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
Rapid Review
| Commenced | Completed | Outcome |
| 13/10/2015 | 02/11/2015 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 04/01/2016 | 06/06/2017 | Reimbursement Not Recommended |
Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.
| The HSE has re-commissioned a full HTA for this product as of 20th March 2018 | |
| Full pharmacoeconomic assessment re-commissioned by HSE | 20/03/2018 |
| Pre-submission consultation with Applicant | 08/10/2018 |
| Submission received from Applicant | 27/02/2019 |
| Current status | HTA assessment ongoing |